Focused On-demand Library for Eukaryotic translation initiation factor 4E type 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O60573

UPID:

IF4E2_HUMAN

Alternative names:

Eukaryotic translation initiation factor 4E homologous protein; Eukaryotic translation initiation factor 4E-like 3; eIF4E-like protein 4E-LP; mRNA cap-binding protein 4EHP; mRNA cap-binding protein type 3

Alternative UPACC:

O60573; B8ZZJ9; O75349

Background:

Eukaryotic translation initiation factor 4E type 2 (EIF4E2) is a pivotal protein in cellular mechanisms, primarily recognized for its role in binding the 7-methylguanosine-containing mRNA cap, a crucial step in the initiation of translation. Unlike EIF4E, EIF4E2 does not bind to eIF4G, indicating its unique function in competing with EIF4E to inhibit the assembly of the eIF4F complex at the mRNA cap. Additionally, EIF4E2 is a key player in miRNA-mediated translational repression and is involved in the cellular response to viral infections, including SARS-CoV-2, by modulating the translation initiation of genes critical to the antiviral immune response.

Therapeutic significance:

Understanding the role of Eukaryotic translation initiation factor 4E type 2 could open doors to potential therapeutic strategies, especially in the context of viral infections and the regulation of immune response genes.